Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of Shensong Yangxin on heart failure in preserved ejection fraction rat model

Weiwei Zhang¹, Qian Sun² , Hao Chen³, Qiang Zhang¹

¹Department of Cardiovascular Medicine; ²Department of Pharmacy, Dezhou People's Hospital; ³Department of Internal Medicine, The People's Hospital of Qingyun County, Dezhou, China.

For correspondence:- Qian Sun Email: Zhangqiangljhyi@163.com

Accepted: 28 November 2018 Published: 26 December 2018

Citation: Zhang W, Sun Q, Chen H, Zhang Q. Effect of Shensong Yangxin on heart failure in preserved ejection fraction rat model. Trop J Pharm Res 2018; 17(12):2427-2432 doi: 10.4314/tjpr.v17i12.17

© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the interventional effect of ShensongYangxin (SSYX) on heart failure (HF) using preserved ejection fraction (HFpEF) rat model.

Methods: HFpEF rat model was established using abdominal aorta coarctation method and randomly divided into a positive drug control group; SSYX at high, medium, and low dosage groups; and normal control group. After 8 weeks oral treatment of SSYX, echocardiography and cardiac catheterization were used to investigate the effects of SSYX on HFpEF rat cardiac functions, including mean heart rate (HR), left ventricle anterior and posterior wall thicknesses at end diastole (LVAWd + LVPWd), left ventricular internal diameter at end diastole (LVIDd), and left ventricle mass (LVM).

Results: SSYX markedly decreased heart weight and improved survival rate (p < 0.01) after 12 weeks of treatment. The expression of NT-proBNP decreased in a dose-dependent manner and was significantly lower in SSYX treatment groups (p < 0.01). Compared with normal control group, expression of CaMK II, PKA and RyR2 was significantly lower (p < 0.005), while expression level of SERCA2a significantly increased after 4 g/kg/day SSYX treatment (p < 0.01).

Conclusion: SSYX significantly attenuates HFpEF-induced cardiac dysfunction and increases survival rate, suggesting that SSYX may prevent HF via regulation of cytoplasmic Ca²⁺ handling. SSYX reduces plasma NT-proBNP levels, lending support for its therapeutic potential in HF management.

Keywords: Heart failure, Ejection fraction, ShensongYangxin